Inflectra Administration Details: Formulation, Potency, Method of Delivery, and Further Information
Inflectra, a biosimilar of infliximab, is approved to treat various autoimmune conditions such as Crohn's disease, ulcerative colitis, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. The dosing schedule for Inflectra generally follows the same guidelines as infliximab because they share the same indications and dosing regimen.
Adult Dosing
For adults with Crohn's disease or ulcerative colitis, the initial loading doses are 5 mg/kg intravenously (IV) at weeks 0, 2, and 6, followed by maintenance doses every 8 weeks. For rheumatoid arthritis, the initial dose is 3 mg/kg IV at weeks 0, 2, and 6, followed by maintenance every 8 weeks in combination with methotrexate. The dosing for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis is the same as for Crohn's disease and ulcerative colitis.
Pediatric Dosing
For children with juvenile idiopathic arthritis, the dosing is weight-based and varies depending on the child's weight. For children weighing between 10–15 kg, the dose is 10 mg every other week, while for children weighing between 15–30 kg, the dose is 20 mg every other week. Children weighing more than 30 kg receive 40 mg every other week.
For pediatric Crohn's disease, the induction doses are weight-based, with doses of 80 mg and 40 mg given on Days 1 and 15, respectively, for children weighing between 17–40 kg, and 160 mg and 80 mg for children weighing 40 kg or more. Maintenance starts on Day 29 with 20 mg or 40 mg every other week.
Comparison to Adalimumab (Humira) Dosing
For reference, the dosing for adalimumab (Humira) is different, with routes and amounts that vary from Inflectra. Here's a comparison table for various conditions:
| Condition | Adult Dose (Adalimumab) | Pediatric Dose (Adalimumab) | |---------------------------|--------------------------------------|-------------------------------------------------------------| | Crohn's Disease | 160 mg Day 1, 80 mg Day 15, then 40 mg EOW | Weight-based; Day 1/15 induction + maintenance 20 or 40 mg EOW | | Rheumatoid Arthritis | 40 mg every other week | Juvenile idiopathic arthritis: 10, 20, or 40 mg EOW by weight | | Plaque Psoriasis | 80 mg initial, then 40 mg every other week | Similar weight-based dosing in children | | Psoriatic Arthritis | 40 mg every other week | As for adults/adults children | | Ulcerative Colitis | Similar to Crohn’s protocol | Weight/age-based maintenance as Crohn’s | | Ankylosing Spondylitis | 40 mg every other week | Generally adult dosing (pediatric use less common) |
Key Points for Inflectra Dosing
- Induction doses typically: 5 mg/kg IV at weeks 0, 2, 6.
- Maintenance: 5 mg/kg IV every 8 weeks.
- Pediatric dosing follows similar weight-based infliximab dosing but should be individualized.
- Inflectra infusions typically take at least 2 hours or more.
For exact Inflectra dosing, healthcare providers consult the specific product labeling for weight, disease, and pediatric adjustments consistent with infliximab guidelines. If you need precise Inflectra dosing for a specific condition, I can provide more detailed Remicade dosing schedules, which serve as the standard reference.
Inflectra is a brand-name prescription medication approved to treat Crohn's disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis in adults. Inflectra's dosage will be calculated based on body weight and is meant to be a long-term treatment.
- Inflectra, a biosimilar for infliximab, treats chronic diseases like Crohn's disease, ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis, among others.
- For adults with Crohn's disease or ulcerative colitis, Inflectra initially requires loading doses of 5 mg/kg intravenously (IV) at weeks 0, 2, and 6, followed by maintenance every 8 weeks.
- Rheumatoid arthritis treatment involves an initial dose of 3 mg/kg IV at weeks 0, 2, and 6, followed by maintenance every 8 weeks in combination with methotrexate.
- Dosing for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis mimics that of Crohn's disease and ulcerative colitis.
- Pediatric dosing for Crohn's disease varies based on weight, whereas for juvenile idiopathic arthritis, the dosage is weight-based and dependent on the child's weight.
- Medical-care providers consult specific product labeling for weight, disease, and pediatric adjustments for Inflectra dosing that aligns with infliximab guidelines.
- Inflectra, developed by AbbVie, is a brand-name prescription drug used to treat adult patients with Crohn's disease, rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis.
- CDI, autoimmune disorders such as rheumatoid arthritis and ulcerative colitis, and chronic diseases are managed with therapies and treatments such as Inflectra, while skin-care regimens and CBD might aid in overall health-and-wellness.
